B. Hershatter

发表

Analysis of Radiation Facility Volume and Survival in Men With Lymph Node–Positive Prostate Cancer Treated With Radiation and Androgen Deprivation Therapy

S. Hanasoge, A. Jani, P. Patel, 2020, JAMA network open.

Overall Survival After Treatment of Localized Prostate Cancer With Proton Beam Therapy, External-Beam Photon Therapy, or Brachytherapy

A. Jani, P. Patel, M. McDonald, 2020, Clinical genitourinary cancer.

High-dose-rate prostate brachytherapy appears safe in patients with high baseline International Prostate Symptom Scores.

M. Sanda, P. Rossi, A. Jani, 2019, Brachytherapy.

The effects of androgen deprivation therapy on cardiac function and heart failure: implications for management of prostate cancer.

J. Butler, S. Edelman, Mohammad K. Khan, 2014, Clinical genitourinary cancer.

Influence of Timing Between Androgen Deprivation Therapy and External Beam Radiation Therapy in Patients With Localized, High-Risk Prostate Cancer

S. Hanasoge, A. Jani, P. Patel, 2020, Advances in radiation oncology.

Association Between Local Radiation Therapy to the Primary Bladder Tumor and Overall Survival for Patients with Metastatic Urothelial Cancer Receiving Systemic Chemotherapy.

V. Arora, J. Picus, J. Christodouleas, 2022, European urology oncology.

18F-fluciclovine-PET/CT imaging versus conventional imaging alone to guide postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a single centre, open-label, phase 2/3 randomised controlled trial

E. Schreibmann, D. Schuster, V. Master, 2021, The Lancet.

Poland's syndrome and lymphoma.

B. Hershatter, G. Montana, 1983, American journal of diseases of children.

Medulloblastoma: the Duke University Medical Center experience.

E. Halperin, E. Cox, B. Hershatter, 1986, International journal of radiation oncology, biology, physics.

EMPIRE-1: Randomized Trial Comparing Conventional- vs Conventional Plus Fluciclovine (18F) PET/CT Imaging-Guided Post-Prostatectomy Radiotherapy for Prostate Cancer

E. Schreibmann, D. Schuster, V. Master, 2021 .

Impact of 18F-Fluciclovine PET/CT Findings on Failure-Free Survival in Biochemical Recurrence of Prostate Cancer Following Salvage Radiation Therapy

D. Schuster, V. Master, A. Jani, 2023, Clinical nuclear medicine.

Treatment Patterns and Overall Survival Outcomes Among Patients Aged 80 yr or Older with High-risk Prostate Cancer

M. Sanda, H. Gay, A. Jani, 2022, European urology open science.

Overall survival comparison between androgen deprivation therapy (ADT) plus external beam radiation therapy (EBRT) vs ADT plus EBRT with brachytherapy boost in clinically node-positive prostate cancer.

O. Kucuk, Stephen Szabo, P. Rossi, 2020, Brachytherapy.

Patient-reported outcomes after Low-dose-rate versus High-dose-rate brachytherapy boost in combination with external beam radiation for intermediate and high risk prostate cancer.

P. Rossi, A. Jani, P. Patel, 2021, Brachytherapy.

Differences in Failure-Free Survival After Salvage Radiotherapy Guided by Conventional Imaging Versus 18F-Fluciclovine PET/CT in Postprostatectomy Patients: A Post Hoc Substratification Analysis of the EMPIRE-1 Trial

D. Schuster, V. Master, A. Jani, 2022, The Journal of Nuclear Medicine.

Initial Report of a Randomized Trial Comparing Conventional- vs Conventional plus Fluciclovine (18F) PET/CT Imaging-Guided Post-Prostatectomy Radiotherapy for Prostate Cancer.

D. Schuster, M. Goodman, O. Kucuk, 2020, International journal of radiation oncology, biology, physics.

Dose-Escalated Radiotherapy Alone or in Combination With Short-Term Androgen Deprivation for Intermediate-Risk Prostate Cancer: Results of a Phase III Multi-Institutional Trial

D. Yan, H. Sandler, M. Lock, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Dose Escalated Radiotherapy Alone or in Combination With Short-Term Androgen Suppression for Intermediate Risk Prostate Cancer: Outcomes From the NRG Oncology/RTOG 0815 Randomized Trial.

A. Martinez, H. Sandler, M. Lock, 2021, International journal of radiation oncology, biology, physics.

Radiation Facility Volume and Survival for Men With Very High-Risk Prostate Cancer Treated with Radiation and Androgen Deprivation Therapy

S. Hanasoge, A. Jani, J. Janopaul-Naylor, 2023, JAMA network open.

Dose-Escalated Radiation Alone or in Combination With Short-Term Total Androgen Suppression for Intermediate-Risk Prostate Cancer: Patient-Reported Outcomes From NRG/Radiation Therapy Oncology Group 0815 Randomized Trial

G. Gustafson, D. Yan, H. Sandler, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

F-18-fluciclovine-PET/CT imaging versus conventional imaging alone to guide postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a single centre, open-label, phase 2/3 randomised controlled trial

E. Schreibmann, D. Schuster, P. Rossi, 2022 .

Dose Escalated Radiotherapy (RT) Alone or in Combination With Short-Term Total Androgen Suppression (TAS) for Intermediate Risk Prostate Cancer: Patient Reported Outcomes (PROs) From the NRG Oncology/RTOG 0815 Randomized Trial.

A. Martinez, H. Sandler, D. Citrin, 2021, International journal of radiation oncology, biology, physics.

Impact of Rectal Spacer on Toxicity Reduction in Men Treated With Proton Versus Photon Therapy

A. Jani, K. Godette, V. Dhere, 2024, International journal of particle therapy.